Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VolATIL: UCPVax and Atezolizumab in HPV+ Cancers
NCT03946358Phase 2Completed
- Sponsor
- CHU de Besançon
- Start
- Feb 2020
- Primary completion
- Mar 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of UCPVax in anal cancer, head and neck squamous cell carcinoma (HNSCC), Cervical Cancer (CC), vulvar cancer, sponsored by CHU de Besançon. Started Feb 2020; status: completed.
02
Drugs
UCPVax
03
Conditions
anal cancerhead and neck squamous cell carcinoma (HNSCC)Cervical Cancer (CC)vulvar cancer
Beyond the preview
Go deeper on NCT03946358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03946358.